Top Pharmaceutical Companies (2,046)
Life Couriers is a global leader in specialized healthcare and life science logistics, dedicated to delivering time-critical diagnostics and therapies. As a premier provider of radiopharmaceutical and stem cell logistics, they offer a broad service portfolio encompassing biopharmaceuticals, cell and gene therapies, clinical trials, and medical devices, all designed to prioritize patient outcomes and ensure the safe, urgent delivery of...
Drugs for Neglected Diseases initiative (DNDi) is an international, not-for-profit research and development organization. It discovers, develops, and delivers affordable treatments for neglected patients worldwide, addressing gaps in drug R&D through collaboration with the international research community, public sector, pharmaceutical industry, and other partners. Its mission focuses on improving health and ensuring equitable access to treatments for people living with...
Clinical ink is the global life science company that brings data, technology, and patient-centric research together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and...
Bluesight enables hospital operations with intelligence that simplifies inventory management, procurement, and compliance. Through its suite of industry-leading, AI-powered solutions, Bluesight ensures that health systems protect every patient and optimize every dollar. Over 3,000 United States and Canadian hospitals rely on Bluesight every day. For more information, please visit bluesight.com. Bluesight's solutions include: KitCheck (inventory management), CostCheck (purchasing optimization), ControlCheck (diversion...
Bluesight's Top Stability & Growth Strengths
Strong Market Position & Advantage: Market leadership is reinforced by extensive adoption across 3,000+ hospitals and health systems in the U.S. and Canada and repeated Best in KLAS recognition for core categories. Category-leading positions in drug diversion monitoring, patient privacy monitoring, and RFID kit/tray management indicate sustained competitive advantage.
Innovation-Driven Growth: Ongoing launches such as the Prism AI platform and embedded generative capabilities for diversion investigations signal continuing innovation in pharmacy and compliance workflows. Additional releases like ShortageCheck, a redesigned 340B platform, and revenue optimization features broaden functionality and drive new use cases.
Strategic Partnerships: Collaborations with AWS, Premier, GraphiteRx/Mark Cuban Cost Plus Drugs, Pharma Logistics, Pfizer, and Healthmark are expanding distribution, capabilities, and ecosystem integration. These partnerships enable automated multi-product workflows and novel commercial arrangements that can accelerate adoption.
Radiant Industries delivers advanced pharmaceutical automation solutions with quality-driven engineering for global healthcare.
ISPV Inc. is a Life Science company that leads Productivity & Validation projects for the Pharmaceutical and Food industries.
Founded in 2001, cGMP Consulting Inc. has strived to help our clients adopt new technologies and ensure that changes to your processes are compliant with current Good Manufacturing Practices (cGMP). Our experienced engineering and quality assurance consultants have helped many industry leading companies identify and remediate gaps, support international pharmaceutical manufacturing, and implement cGMP requirements.
PSI is a leading full-service global Contract Research Organization whose key strength is predictable patient enrollment across multiple therapeutic areas. PSI is known in the industry as a CRO focused on ‘on-time project delivery’. This is achieved through investing substantial effort and MD resources into performing quality feasibility assessments that provide an accurate predictor of study timelines. PSI’s global reach allows us...
Pierre Fabre Group held by the Pierre Fabre Foundation, is a worldwide company with a unique positioning : the alliance of pharmaceutical and dermocosmetics expertise. This makes Pierre Fabre Group : A pharmaceutical group with a strong positioning : medical and natural The second largest dermo-cosmetics laboratory in the world The second largest private French pharmaceutical group The market leader...
Tarrytown Expocare LLC is a long-term care pharmacy that dispenses medicinal preparations to patients in intermediate or skilled nursing facilities and serves IDD communities.
Meadowhawk Biolabs, Inc. is a contract research organization (CRO) that provides bioanalytical, pharmacokinetic, and pharmacological laboratory services to biotechnology and pharmaceutical companies involved in drug discovery and development.
At Solventum, we enable better, smarter, safer healthcare to improve lives. We never stop solving for you
Solventum's Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is a leader or co‑leader in core niches such as negative‑pressure wound therapy and hospital coding/CDI software, with widely deployed platforms and recognized standings. Brand strength and installed bases across MedSurg, Dental, and HIS reinforce competitive positioning.
Resilient & Sustainable Growth: Recent quarters show positive organic sales growth, and guidance points to continued low‑single‑digit expansion. Feedback suggests momentum is supported across key segments, aligning with a steady, incremental trajectory.
Future-Ready Strategy: Management outlines a multi‑year plan centered on portfolio focus, R&D‑led innovation, and selective M&A to accelerate growth. Actions such as SKU rationalization, product launches, and targeted partnerships indicate preparation for longer‑term expansion.
CFG Health Systems, LLC is a privately-held correctional healthcare provider specializing in delivering high-quality medical, behavioral health, and dental services to incarcerated persons and detained juveniles. Founded in 1999, the company emphasizes holistic care and is a pioneer in utilizing telehealth services to enhance accessibility and efficiency in delivering care within correctional facilities across the region, focusing on improving the...
True Rx Health Strategists is a pharmacy benefits manager for employee benefit brokers and self-insured employers who refuse to accept the health care paradox: spending more on pharmacy benefits while employees get sicker. As Health Strategists, we deliver transparent pricing and proactive, pharmacist-led solutions guided by clinical expertise, not financial incentives. Where traditional PBMs process claims, we solve health...
.png){kind=logo}
KreaMedica provides the following services: ► Hands-on project management and monitoring services ► Access to a network of external experts ► Functional outsourcing services for non-clinical and clinical development
KreaMedica Inc.'s Top Stability & Growth Strengths
Market Expansion: Industry listings show active participation in major partnering forums (e.g., BIO International 2026) and outreach into APAC, signaling ongoing footprint expansion. Visibility metrics like rising LinkedIn followers further suggest growing market presence.
Innovation-Driven Growth: The company is building out KreaConnect to match sponsors with vetted experts and to productize parts of its offering. This platform-plus-network approach indicates innovation-led expansion beyond pure consulting.
Strong Hiring & Retention: Recent hiring activity includes a new Director of Business Development and an open Junior BD & CRM role. These additions point to near-term capacity scaling consistent with growth.
The Bill & Melinda Gates Medical Research Institute is a non-profit organization dedicated to the development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited. The institute works through collaborating partners and organizations, coordinating and driving the full spectrum of biopharmaceutical development activities, including pre-clinical development, full clinical development (from phase...
Rancho BioSciences is an international fee for service data curation company with analysis and developer services. Our customers include Pharma, Foundations, Government and Biotech. We have a team of experienced PhD and PhD/MD scientists around the world that deliver high quality work based on their expertise and domain knowledge in biology, diseases and clinical data. Rancho BioSciences is flexible and cost...
JAMP Pharma Group is a private Canadian company founded in 1988, originally a contract manufacturing organization. It is a leading generic player in the Canadian pharmaceutical industry, providing high-quality, affordable medicines and health solutions.
There are two Otsuka pharmaceutical industry companies in the U.S.: Otsuka America Pharmaceutical, Inc. (OAPI) successfully commercializes Otsuka-discovered and in-licensed products in North America. Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) clinically develops and registers innovative healthcare products on a global basis.
Otsuka America Pharmaceutical's Top Stability & Growth Strengths
Strong Revenue Growth: Recent disclosures indicate double-digit growth at the parent level with North America identified as the largest and expanding region. Management attributes momentum to U.S.-marketed medicines such as REXULTI, ABILIFY MAINTENA, and JYNARQUE powering the pharmaceutical segment.
Strong Market Position & Advantage: The company is repeatedly portrayed as a leader in mental health and nephrology, supported by first-in-class and category-defining therapies. Flagship assets like aripiprazole long-acting injectables, REXULTI’s Alzheimer’s agitation indication, and JYNARQUE underpin durable positioning in core niches.
Innovation-Driven Growth: Multiple approvals, priority reviews, and acquisitions underscore an active pipeline across CNS and renal diseases. Examples include FDA priority review for centanafadine, accelerated approval for sibeprenlimab, digital therapeutic launches, and targeted deals to strengthen U.S. capabilities.
At Astellas, we strive to be a cutting-edge, value-driven life science innovator. This means working at the forefront of healthcare change to turn innovative science into the best outcomes for patients. Operating in approximately 70 countries with more than 14,000 employees, we are relentless in our pursuit of scientific progress and in tackling unmet medical needs. Visit our Global Astellas...
Astellas Pharma's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue reached a record level in FY2024 with double‑digit year‑over‑year growth, and management raised FY2025 guidance after continued momentum through the first nine months. Company updates attribute this to strong contributions from “Strategic Brands” including PADCEV, VYLOY, VEOZAH, IZERVAY and sustained XTANDI demand.
Profitability: Core operating profit increased markedly faster than sales in FY2025 year‑to‑date, reflecting margin expansion. Management links improvement to mix benefits from strategic brands and cost programs such as the Sustainable Margin Transformation initiative.
Strong Market Position & Advantage: Astellas demonstrates category leadership in niches—XTANDI in prostate cancer and PADCEV + Keytruda setting a new first‑line standard in advanced urothelial cancer with later perioperative expansion. First‑in‑class positions in CLDN18.2 gastric cancer (VYLOY) and non‑hormonal menopause therapy (VEOZAH) further strengthen its competitive footing.
